Chinook Therapeutics gets orphan drug status from EC for atrasentan in IgAN

Chinook Therapeutics, a US-based biopharma company, has secured orphan drug designation for atrasentan from the European Commission (EC) for the treatment of primary IgA nephropathy ... Read More